FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like DexCom Reports First Quarter 2017 Financial Results May 2, 2017 Two-Year Old Biotech NousCom Nabs $49M to Fund New Drug Into Clinic November 5, 2017 SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission December 7, 2017
